14 November 2023 - trading update
The AIM-listed specialist infection protection and control company has reported an update on trading ahead of the announcement of its interim results next month. This has shown that product sales in the period to 30 September are expected to be around £2m, a similar level to 2022. This reflects the impact of discontinued items. An EBITDA loss of £0.45m is expected compared with a loss of £0.3m last year although cash in the bank should be around £0.5m. For the full year to 31 March 2024, product sales are expected to . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
